Cargando…
Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?
SIMPLE SUMMARY: Renal cell carcinoma (RCC) is the most common form of kidney cancer, characterized by silent progression at early stages, heterogeneous behavior and resistance to chemotherapy and radiotherapy. The clinical challenges posed by RCC require the development of a novel class of biomarker...
Autores principales: | Couto-Cunha, Anabela, Jerónimo, Carmen, Henrique, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818240/ https://www.ncbi.nlm.nih.gov/pubmed/36612281 http://dx.doi.org/10.3390/cancers15010287 |
Ejemplares similares
-
The Epigenetics of Renal Cell Tumors: from Biology to Biomarkers
por: Henrique, Rui, et al.
Publicado: (2012) -
Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma
por: Sequeira, José Pedro, et al.
Publicado: (2021) -
Cancer Biomarkers: Are We Ready for the Prime Time?
por: Mishra, Alok, et al.
Publicado: (2010) -
Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs
por: Outeiro-Pinho, Gonçalo, et al.
Publicado: (2020) -
Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)